Evidence map›Paper›PMID 18509635›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2008

Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for 68Ga-labeled small recombinant antibodies.

Matthias Eder, Björn Wängler, Stefan Knackmuss, Fabrice LeGall, Melvyn Little, Uwe Haberkorn, Walter Mier, Michael Eisenhut

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. The diagnostic performance ofFrontiers in oncology · 2023
    Article
  8. Article
  9. Review
  10. Article
  11. Cold Kit Labeling: The Future ofFrontiers in medicine · 2022
    Review
  12. Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Development ofChemical science · 2019
    Article
  20. Instant kit preparation ofEJNMMI research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Matthias EderRadiopharmaceutical Chemistry, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. m.eder@dkfz.de
Björn Wängler
Stefan Knackmuss
Fabrice LeGall
Melvyn Little
Uwe Haberkorn
Walter Mier
Michael Eisenhut
Affimed Therapeutics (Germany) · DEHeidelberg University · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe success of (68)Ga-labeled peptides for positron emission tomography of neuroendocrine tumors is mainly depending on the complex chemistry of this radioisotope. 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), the chelator of choice has however limitations if its application is expanded to heat-sensitive proteins. Recombinant antibodies like single chain Fv or diabodies belong to this class of proteins. They are suited to provide imaging contrast despite the short-lived (68)Ga because of their rapid blood clearances and nanomolar affinities. The heterobifunctional agent N,N'-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid (HBED-CC) was chosen as an alternative ligand because this agent is complexing [(68)Ga]Ga(3+) much faster than DOTA at ambient temperatures. MATERIALS AND

methodsA versatile technology for HBED-CC conjugation of proteins and (68)Ga-labeling has been developed. This included HBED-CC-tetrafluorophenol (TFP) ester synthesis, coupling to the antibody at various pH and complexation reactions performed in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer under different conditions.

resultsThe synthesis of the monoreactive 2,3,5,6-tetrafluorophenolate of HBED-CC at a carboxyl group not participating in complex formation used [Fe(HBED-CC)](-) for ester formation. The removal of Fe(3+) from purified (HBED-CC)TFP ester was achieved with RP(18) cartridge technology. The conjugation chemistry was performed with mAb425 which binds to the epidermal growth factor receptor (EGFR). This protein was used for optimizing purposes only. The influence of complexation parameters like temperature, pH, reaction time, and HBED-CC/antibody ratio on the biological activity of this model antibody was investigated. Furthermore, the outcome of this labeling procedure on the biological activity of a recombinant diabody (50 kDa) was studied.

conclusionIt is known that small HBED-CC/antibody ratios are prerequisites for minimal interference of labels with antigen-binding domains. Here, the coupling of about one HBED-CC per antibody proved to be sufficient for efficient (68)Ga labeling, pointing to the successful application of (68)Ga for molecular imaging with small recombinant proteins.

Indexed as

AntibodiesEdetic AcidGallium RadioisotopesHeterocyclic Compounds, 1-RingIsotope LabelingPeptidesRadiopharmaceuticalsRecombinant Proteins1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidAntibodiesEdetic AcidGallium RadioisotopesHeterocyclic Compounds, 1-RingN,N'-bis(2-hydroxy-5-(ethylene-beta-carboxy)benzyl)ethylenediamine N,N'-diacetic acidPeptidesRadiopharmaceuticalsRecombinant Proteins

Identifiers

PMID18509635
OpenAlexW2052933378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.